DTCA on trial: Addressing the issues

By Stephen P. Makk, MD, MBA

Two recent articles in AAOS NOW—“DTCA: Improving patient education or simply increasing pharmaceutical profits?” (December 2007) and “Give them what they need, not what they ask for” (January 2008)—piqued my interest and begged for additional discussion and clarification. Together, they put direct-to-consumer advertising (DTCA) on trial while leaving room for additional, valuable discussion points.

This content is only available to members of the AAOS.

Please log in using the link at the top right corner of this page to access your exclusive AAOS member content.

Not a member? Become a member!

Advertisements


Advertisement